PMEG for Repair of Pararenal and Thoracoabdominal Aortic Aneurysm
Key facts
- Where
- Wesley Chapel, United StatesSee the site
Where in United States
- Orlando Health Wiregrass Ranch HospitalWesley Chapel, United StatesContact: TIna HendersonTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Konstantinos Arnaoutakis, MD
- Trial code
- NCT05195905
- Record updated
- 16 October 2026
- Original description
The primary objective is to evaluate the safety and effectiveness of surgeon modified endografts for the treatment of pararenal and thoracoabdominal aortic pathology in patients who are not candidate for traditional open repair due to comorbid issues and their anatomy is not amenable to commercially available endografts.Read full original descriptionShow less
Evaluation of Spinal Cord Ischemia and Mortality and Morbidity After Endovascular Repair of Pararenal and Thoracoabdominal Aortic Aneurysm Using Surgeon-Modified Endografts
The primary objective is to evaluate the safety and effectiveness of surgeon modified endografts for the treatment of pararenal and thoracoabdominal aortic pathology in patients who are not candidate for traditional open repair due to comorbid issues and their anatomy is not amenable to commercially available endografts.
Inclusion: Provision of signed and dated informed consent form; Male or female, aged ≥18 years; Expected survival beyond 1 year following successful aneurysm repair; Anatomy that would require coverage of the celiac artery, superior mesenteric artery (SMA), and/or renal arteries if conventional, FDA-approved endograft were implanted to obtain adequate sealing zone length; Aneurysm of the thoracoabdominal or pararenal aorta with or without chronic dissection; Adequate proximal zone of fixation; Adequate distal zone of fixation; No more than 5 non-aneurysmal visceral (celiac, SMA, or renal) arteries with diameters between 4-12mm; Adequate arterial access for delivery system; use of iliac conduit is permitted as necessary.
Exclusion: Pregnancy or lactation (confirmed per standard of care surgical practice); Major, unrelated surgical procedure planned ≤30 days from endovascular repair; Patient is ≤30 days beyond primary endpoint for another investigative clinical drug/device trial; Unstable angina; Stroke or MI within 3 months of planned treatment date; Active systemic infection and/or mycotic aneurysm; Uncorrectable coagulopathy or other bleeding diathesis; Known allergy to device material or contrast material that cannot be adequately pre-medicated; Baseline eGFR < 30ml/min, unless currently on or to be initiating dialysis; Moderate-to-severe aortic neck calcification, thrombus, or tortuosity; Severe iliac stenosis, calcification, or tortuosity with no ability to perform a conduit; Proximal landing within zone 0 or 1; Inability to maintain at least one patent hypogastric artery; Freely ruptured aneurysm with hemodynamic instability; Non-ambulatory status; Severe CHF; Body habitus that would preclude adequate fluoroscopic visualization of aorta; Social or psychological issues that would interfere with ability to comply with all study procedures for the duration of the study; Can be treated in accordance with the instructions for use with a legally marketed endovascular device, including a manufacturer-fabricated custom device; Can enroll in a manufacturer-sponsored clinical study at our institution or is willing and eligible to participate in a study with a manufacturer-made device at another institution.